Ignacio Melero
Impact in
- Immunology top 0.02%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
- T-cell and B-cell Immunology
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
- Oncology 244
- Cancer Immunotherapy and Biomarkers 143
- CAR-T cell therapy research 117
- Immunology 236
- Immunotherapy and Immune Responses 165
- Immune Cell Function and Interaction 99
- T-cell and B-cell Immunology 56
- Co-authors
- José Luis Perez‐Gracia (71 shared papers)Bruno Sangro (55 shared papers)Miguel F. Sanmamed (64 shared papers)María E. Rodríguez-Ruiz (63 shared papers)Sandra Hervás‐Stubbs (46 shared papers)Jesús Prìeto (48 shared papers)David Sancho (13 shared papers)Lieping Chen (19 shared papers)
- Journals
- Journal of Clinical Oncology (40 papers)Annals of Oncology (36 papers)Journal for ImmunoTherapy of Cancer (28 papers)Cancer Research (23 papers)Clinical Cancer Research (20 papers)
- Partner nations
- SpainUnited StatesUnited Kingdom
In The Last Decade
Ignacio Melero
393 papers receiving 29.5k citations
Ignacio Melero's Hit Papers
Peers
Comparison fields: 5 of 159
- Immunology 16.0k
- Oncology 14.6k
- Hepatology 2.2k
- Cancer Research 1.9k
- Biotechnology 938
Countries citing papers authored by Ignacio Melero
This map shows the geographic impact of Ignacio Melero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ignacio Melero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ignacio Melero more than expected).
Fields of papers citing papers by Ignacio Melero
This network shows the impact of papers produced by Ignacio Melero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ignacio Melero. The network helps show where Ignacio Melero may publish in the future.
Co-authors
The 25 scholars most cited alongside Ignacio Melero, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 406 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Dendritic cells in cancer immunology and immunotherapy Hit paper breakdown → | 2019 | 1933 |
| 2 | Advances in immunotherapy for hepatocellular carcinoma Hit paper breakdown → | 2021 | 917 |
| 3 | Cytokines in clinical cancer immunotherapy Hit paper breakdown → | 2018 | 905 |
| 4 | A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C Hit paper breakdown → | 2013 | 790 |
| 5 | Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors Hit paper breakdown → | 1997 | 763 |
| 6 | Therapeutic vaccines for cancer: an overview of clinical trials Hit paper breakdown → | 2014 | 643 |
| 7 | Cancer vaccines: the next immunotherapy frontier Hit paper breakdown → | 2022 | 601 |
| 8 | Evolving synergistic combinations of targeted immunotherapies to combat cancer Hit paper breakdown → | 2015 | 518 |
| 9 | Immunostimulatory monoclonal antibodies for cancer therapy Hit paper breakdown → | 2007 | 514 |
| 10 | Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes Hit paper breakdown → | 2019 | 485 |
| 11 | Immunological landscape and immunotherapy of hepatocellular carcinoma Hit paper breakdown → | 2015 | 481 |
| 12 | Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma Hit paper breakdown → | 2019 | 464 |
| 13 | 2011 | 385 | |
| 14 | Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect Hit paper breakdown → | 2018 | 378 |
| 15 | 2015 | 373 | |
| 16 | 2014 | 366 | |
| 17 | Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors Hit paper breakdown → | 2020 | 365 |
| 18 | Intratumoural administration and tumour tissue targeting of cancer immunotherapies Hit paper breakdown → | 2021 | 360 |
| 19 | 2017 | 356 | |
| 20 | Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint Hit paper breakdown → | 2020 | 351 |
About Ignacio Melero
Ignacio Melero is a scholar working on Oncology, Immunology, Molecular Biology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 406 papers that have together received 30.0k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (165 papers), Cancer Immunotherapy and Biomarkers (143 papers), CAR-T cell therapy research (117 papers), Immune Cell Function and Interaction (99 papers), T-cell and B-cell Immunology (56 papers), Virus-based gene therapy research (37 papers), Hepatocellular Carcinoma Treatment and Prognosis (28 papers) and Monoclonal and Polyclonal Antibodies Research (25 papers). The work is most often cited by research in Immunology (16.0k citations), Oncology (14.6k citations), Hepatology (2.2k citations), Cancer Research (1.9k citations) and Biotechnology (938 citations). Ignacio Melero has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include José Luis Perez‐Gracia, Bruno Sangro, Miguel F. Sanmamed, María E. Rodríguez-Ruiz, Sandra Hervás‐Stubbs, Jesús Prìeto, David Sancho, Lieping Chen, Francisco J. Cueto and Pedro Berraondo. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal for ImmunoTherapy of Cancer, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.